Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped [Yahoo! Finance]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Yahoo! Finance
Current runners-up Viking Therapeutics (NASDAQ: VKTX) and Roche Holdings (OTC: RHHBY) , up 11.3% and 4%, respectively, through 10:05 a.m. ET today, are behind it. And Novo Nordisk (NYSE: NVO) stock, down 4.9%, is the victim. Good news for Viking Let's start with the background. Currently there are four branded and patent-protected GLP-1 weight-loss drugs on the market. Novo Nordisk owns two of them: Ozempic and Wegovy. Eli Lilly (NYSE: LLY) owns the other two: Mounjaro and Zepbound. Both Viking and Roche are attempting to horn in on this market, however. Yesterday, Viking signed a "broad manufacturing agreement" with Germany's CordenPharma to produce for it a "multi-ton annual supply" of Viking's own VK2735 GLP-1 weight-loss drug. VK2735 is still in clinical trials and not yet available for general sale, but Viking seems confident the drug will come to market and has hired CordenPharma to produce for it up to: 100 million autoinjectors annually 100 million units of vials
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Viking Therapeutics, Inc. (NASDAQ: VKTX) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.MarketBeat
- Viking Therapeutics, Inc. (NASDAQ: VKTX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $104.00 price target on the stock.MarketBeat
- Why Viking Therapeutics Stock Popped Today [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics, Inc. (NASDAQ: VKTX) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $75.00 price target on the stock, down previously from $95.00.MarketBeat
- Viking Therapeutics, Inc. (NASDAQ: VKTX) had its price target lowered by analysts at Morgan Stanley from $105.00 to $102.00. They now have an "overweight" rating on the stock.MarketBeat
VKTX
Earnings
- 4/23/25 - Miss
VKTX
Sec Filings
- 4/24/25 - Form 10-Q
- 4/23/25 - Form DEFA14A
- 4/23/25 - Form DEFR14A
- VKTX's page on the SEC website